Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852810 | 1.00 | MAOA (0.35) | MAOAMAOBCYP2A6HTR2AHTR2C | |
| SCHEMBL29591293 | 0.72 | MAOA (0.46) | MAOAMAOBCYP2A6HTR2AHTR2C | |
| SCHEMBL4419988 | 0.72 | MAOA (0.46) | MAOAMAOBCYP2A6HTR2AHTR2C | |
| SCHEMBL793638 | 0.72 | CYP2A6 (0.46) | CYP2A6ADORA2AADORA1 | |
| SCHEMBL23218142 | 0.72 | MAOA (0.43) | MAOAMAOBCYP2A6HTR2AHTR2C | |
| SCHEMBL30644302 | 0.71 | MAOA (0.41) | MAOAMAOBCYP2A6HTR2AHTR2C | |
| SCHEMBL15834704 | 0.71 | MAOA (0.41) | MAOAMAOBCYP2A6HTR2AHTR2C | |
| SCHEMBL4430227 | 0.70 | ADORA2A (0.35) | MAOAMAOBADORA2AADORA1 | |
| SCHEMBL4416788 | 0.70 | MET (0.32) | — | |
| SCHEMBL29001094 | 0.68 | MAOA (0.32) | MAOAMAOBHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351266-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2008-04-01 | — | — | US | claimed |
| EP-1720615-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2006-11-15 | — | — | EP | claimed |
| WO-2005087187-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050193504-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-08 | — | — | US | claimed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-1720615-B1 | COSMETIC HAIR DYEING COMPOSITIONS CONTAINING THEM AND USE THEREOF | PROCTER & GAMBLE (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7468080-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080134450-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof | WELLA OPERATIONS US, LLC | 2008-06-12 | — | — | US | disclosed |
| US-7351266-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1720615-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005087187-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050193504-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050193504-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, KRTCAP2 | MAOA 507/4885MAOB 1003/4885CYP2A6 405/4885 |
| US-20080134450-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof | KRT18, CKMT1A; CKMT1B, KRTCAP2 | MAOA 507/4885MAOB 1003/4885CYP2A6 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.